Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers

#VERAXA Biotech and Voyager Acquisition Corp Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 ' In a significant development for the biopharmaceutical sector, VERAXA Biotech AG (VERAXA), a dynamic player in the design of innovative cancer therapies, has entered into a definitive busine…

Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers

TORONTO, ONTARIO - April 24, 2025 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointments of Veronika Kandziora as Chief Operating Officer (“COO”) and Jessica Kourniaktis, DPhil, as Director of Communications of the Company. Ms. Kandziora is a seas…